Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors

Abstract

BIIB028 is a well-tolerated molecule that showed target impact and was associated with prolonged stable disease in two patients.